Meda AB (MDABF.PK) said the US Food and Drug Administration has approved Edluar for the short-term treatment of insomnia.
The product contains the well-known substance zolpidem and uses Orexo's patented sublingual tablet formulation.
The company said that the collaboration agreement with Orexo entitles them to a milestone payment at FDA approval. That milestone is US$5 million based on the product labelling. No further milestone payments for Edluar are expected to be due Orexo.
Product launch in the US is anticipated to start during 2nd half of 2009.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.